Drug Profile
MOL 376
Latest Information Update: 14 Mar 2008
Price :
$50
*
At a glance
- Originator Molecumetics
- Class Benzothiazoles
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis; Unstable angina pectoris
Most Recent Events
- 30 Nov 2002 No development reported - Preclinical for Deep vein thrombosis in Japan (PO)
- 30 Nov 2002 No development reported - Preclinical for Deep vein thrombosis in USA (PO)
- 30 Nov 2002 No development reported - Preclinical for Unstable angina pectoris in Japan (PO)